Skip to content
mapperlab
← Dashboard
Stock

TDOC

TELADOC HEALTH, INC.
Latest close $7.557 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
7
27 funds tracked
Ever held
10
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

May 15, 2017Feb 16, 2021Nov 14, 2024May 15, 2026
Now
8

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Bridgewater Associates$294$7.55-97%
Renaissance Technologies$7.15$7.55+6%
Citadel Advisors$6.79$7.55+11%
D.E. Shaw re-entered$6.79$7.55+11%
AQR Capital Management$6.79$7.55+11%
Point72 Asset Management$6.79$7.55+11%
Two Sigma Investments$14$7.55-47%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Millennium Management 3× in & out+0%
Maverick Capital 3× in & out→ $8.96-71%
Tiger Global→ $49+70%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Teladoc Health, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
13
Filings · last 90d
17
Total on file
525
Recent SEC buffer
Most recent
Jun 4, 2026

30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 525 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · TELADOC HEALTH, INC.

Annual figures sourced directly from TELADOC HEALTH, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$2.53B
FY2025-2% YoY
Net income
-$200.32M
FY2025+80% YoY
EPS (diluted)
$-1.14
FY2025+81% YoY
Free cash flow(?)
$285.46M
FY2025+1% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Teladoc Health, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Millennium ManagementQ4 2025Q1 2026$0.00+0%
Two Sigma InvestmentsQ1 2025open$14$6.35-56%
D.E. ShawQ4 2024open$0.00+0%
Millennium ManagementQ4 2024Q2 2025$0.00+0%
Citadel AdvisorsQ3 2024open$6.79$6.35-6%
D.E. ShawQ3 2024open$6.79$6.35-6%
AQR Capital ManagementQ3 2024open$6.79$6.35-6%
Millennium ManagementQ3 2024Q2 2026$6.79$6.36-6%
Point72 Asset ManagementQ3 2024open$6.79$6.35-6%
Renaissance TechnologiesQ3 2024open$7.15$6.35-11%
Maverick CapitalQ1 2023Q4 2024$30$8.96-71%
Maverick CapitalQ1 2021Q2 2021$291$137-53%
Bridgewater AssociatesQ1 2021open$294$7.55-97%
Maverick CapitalQ3 2020Q4 2020$188$177-6%
Tiger GlobalQ2 2017Q2 2018$29$49+70%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.